Logicbio Stock Analysis

LOGC -  USA Stock  

USD 4.19  0.06  1.41%

The big decline in price over the last few months for Logicbio Therapeuticsmay encourage investors to take a closer look at the firm as it is trading at a share price of 4.19 on 100,892 in trading volume. The company executives failed to add value to investors and positioning the firm supply of money to exploit market volatility in May. However, diversifying your holdings with Logicbio Therapeutics or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.79. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Logicbio Therapeutics partners.
Additionally, see Stocks Correlation.

Search Stock Analysis 

 
Refresh
The Logicbio Therapeutics stock analysis report makes it easy to digest most publicly released information about Logicbio Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Logicbio stock analysis module also helps to analyze the Logicbio Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Logicbio Stock Analysis Notes

About 14.0% of the company outstanding shares are owned by corporate insiders. The book value of Logicbio Therapeutics was now reported as 1.93. The company recorded a loss per share of 1.29. Logicbio Therapeutics had not issued any dividends in recent years. LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts. Logicbio Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs people. To find out more about Logicbio Therapeutics contact William Volz at 617 245 0399 or learn more at http://www.logicbio.com.

Logicbio Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Logicbio Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Logicbio Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Logicbio Therapeutics generates negative expected return over the last 90 days
Logicbio Therapeutics has high historical volatility and very poor performance
Logicbio Therapeutics has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 3.45 M. Net Loss for the year was (32.62 M) with profit before overhead, payroll, taxes, and interest of 3.45 M.
Logicbio Therapeutics currently holds about 70.08 M in cash with (28.93 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.19.
Logicbio Therapeutics has a frail financial position based on the latest SEC disclosures
Roughly 65.0% of the company shares are owned by institutional investors
Latest headline from www.equities.com: LogicBio Therapeutics Inc falls -0.2250 percent for June 15 - Equities.com

Logicbio Therapeutics Upcoming and Recent Events

Earnings reports are used by Logicbio Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Logicbio Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report9th of August 2021
Next Earnings Report8th of November 2021
Next Fiscal Quarter End30th of June 2021
Next Fiscal Year End21st of March 2022
Last Quarter Report31st of March 2021
Last Earning Announcement30th of June 2020

Logicbio Largest EPS Surprises

Earnings surprises can significantly impact Logicbio Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2019-08-13
2019-06-30-0.4-0.45-0.0512 
2019-05-14
2019-03-31-0.2875-0.34-0.052518 
2021-05-10
2021-03-31-0.2633-0.32-0.056721 
View All Earnings Estimates

Logicbio Therapeutics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Logicbio Therapeutics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Logicbio Therapeutics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Logicbio Therapeutics specific information freely available to individual and institutional investors to make a timely investment decision.
2nd of June 2021
Financial Statements and Exhibits. Other Events. Regulation FD Disclosure
View
10th of May 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
29th of April 2021
Entry into a Material Definitive Agreement
View
15th of March 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
16th of February 2021
Unclassified Corporate Event
View
12th of February 2021
Unclassified Corporate Event
View
11th of February 2021
Unclassified Corporate Event
View
1st of February 2021
Unclassified Corporate Event
View

Logicbio Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Logicbio Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Logicbio Therapeutics backward and forwards among themselves. Logicbio Therapeutics' institutional investor refers to the entity that pools money to purchase Logicbio Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Orbimed Advisors LlcCommon Shares8.5 M61.6 M
Franklin Resources IncCommon Shares1.6 M11.6 M
Samlyn Capital LlcCommon Shares1.4 M10.2 M
Blackrock IncCommon Shares984 K7.2 M
Vanguard Group IncCommon Shares799.7 K5.8 M
Ecor1 Capital LlcCommon Shares688.7 KM
Fmr LlcCommon Shares500 K3.6 M
Note, although Logicbio Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Logicbio Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 147.62 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Logicbio Therapeutics's market, we take the total number of its shares issued and multiply it by Logicbio Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Logicbio Profitablity

Logicbio Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Logicbio Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Logicbio Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Logicbio Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Logicbio Therapeutics' profitability requires more research than a typical breakdown of Logicbio Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2021
Return on Average Assets(0.60) (0.65) 
Return on Average Equity(0.90) (0.92) 
Return on Invested Capital(1.75) (1.80) 
Return on Sales(8.16) (8.81) 

Management Efficiency

The entity has return on total asset (ROA) of (28.9) % which means that it has lost $28.9 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (62.91) %, meaning that it created substantial loss on money invested by shareholders. Logicbio Therapeutics management efficiency ratios could be used to measure how well logicbio therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of June 17, 2021, Return on Average Assets is expected to decline to -0.65. In addition to that, Return on Average Equity is expected to decline to -0.92. Logicbio Therapeutics Assets Non Current are projected to increase significantly based on the last few years of reporting. The past year's Assets Non Current were at 8.1 Million. The current year Tangible Assets Book Value per Share is expected to grow to 3.26, whereas Total Assets are forecasted to decline to about 71.1 M.
Last ReportedProjected for 2021
Book Value per Share 2.42  2.22 
Enterprise Value over EBIT(7.00) (7.55) 
Enterprise Value over EBITDA(7.74) (8.35) 
Price to Book Value 3.95  4.15 
Tangible Assets Book Value per Share 3.18  3.26 
Enterprise Value225.9 M230.8 M
Tangible Asset Value80.6 M71.1 M

Technical Drivers

As of the 17th of June 2021, Logicbio Therapeutics secures the mean deviation of 3.23, and Risk Adjusted Performance of (0.13). In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Logicbio Therapeutics, as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We were able to analyze and collect data for nineteen technical drivers for Logicbio Therapeutics, which can be compared to its peers in the industry. Please verify Logicbio Therapeutics standard deviation, value at risk, kurtosis, as well as the relationship between the jensen alpha and semi variance to decide if Logicbio Therapeutics is priced some-what accurately, providing market reflects its recent price of 4.19 per share. Given that Logicbio Therapeutics has jensen alpha of (0.87), we recommend you to check Logicbio Therapeutics's last-minute market performance to make sure the company can sustain itself at a future point.

Logicbio Therapeutics Price Movement Analysis

The output start index for this execution was fourty-nine with a total number of output elements of twelve. The Exponential Moving Average is calculated by weighting recent values of Logicbio Therapeutics more heavily than older values. View also all equity analysis or get more info about exponential moving average overlap studies indicator.

Logicbio Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Logicbio Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Logicbio Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Logicbio Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Karydas Daphne 3 days ago via Macroaxis 
Acquisition by Karydas Daphne of 12500 shares of Logicbio Therapeutics subject to Rule 16b-3
Gruskin Daniel over three weeks ago via Macroaxis 
Acquisition by Gruskin Daniel of 60000 shares of Logicbio Therapeutics subject to Rule 16b-3
Paul Andrea over three weeks ago via Macroaxis 
Acquisition by Paul Andrea of 165000 shares of Logicbio Therapeutics subject to Rule 16b-3
Chiang Kyle over a month ago via Macroaxis 
Exercise or conversion by Chiang Kyle of 9360 shares of Logicbio Therapeutics subject to Rule 16b-3
Jones Cecilia over three months ago via Macroaxis 
Acquisition by Jones Cecilia of 78000 shares of Logicbio Therapeutics subject to Rule 16b-3
Jones Cecilia over three months ago via Macroaxis 
Acquisition by Jones Cecilia of 59 shares of LogicBio Therapeutics subject to Rule 16b-3
Quick Jonathan over three months ago via Macroaxis 
LogicBio Therapeutics exotic insider transaction detected
Kay Mark A over three months ago via Macroaxis 
Exercise or conversion by Kay Mark A of 2199 shares of LogicBio Therapeutics subject to Rule 16b-3
Karydas Daphne over six months ago via Macroaxis 
Acquisition by Karydas Daphne of 20000 shares of LogicBio Therapeutics subject to Rule 16b-3
Nacht Mariana over six months ago via Macroaxis 
Acquisition by Nacht Mariana of 200000 shares of LogicBio Therapeutics subject to Rule 16b-3
Chiang Kyle over six months ago via Macroaxis 
Acquisition by Chiang Kyle of 85000 shares of LogicBio Therapeutics subject to Rule 16b-3
Chimovits Erez over six months ago via Macroaxis 
Purchase by Chimovits Erez of 296296 shares of LogicBio Therapeutics

Logicbio Therapeutics Predictive Daily Indicators

Logicbio Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Logicbio Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Logicbio Therapeutics Forecast Models

Logicbio Therapeutics time-series forecasting models is one of many Logicbio Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Logicbio Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Logicbio Therapeutics Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Logicbio Therapeutics stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Logicbio shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Logicbio Therapeutics. By using and applying Logicbio Stock analysis, traders can create a robust methodology for identifying Logicbio entry and exit points for their positions.
Last ReportedProjected for 2021
EBITDA Margin(7.61) (8.21) 
Gross Margin 0.90  0.89 
Profit Margin(8.50) (9.17) 
LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts. Logicbio Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs people.

Current Logicbio Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Logicbio analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Logicbio analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
17.75Strong Buy4Odds
Logicbio Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Logicbio analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Logicbio stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Logicbio Therapeutics, talking to its executives and customers, or listening to Logicbio conference calls.
Logicbio Analyst Advice Details

Logicbio Stock Analysis Indicators

Logicbio Therapeutics stock analysis indicators help investors evaluate how Logicbio Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Logicbio Therapeutics shares will generate the highest return on investment. By understating and applying Logicbio Therapeutics stock analysis, traders can identify Logicbio Therapeutics position entry and exit signals to maximize returns.
Quick Ratio11.43
Fifty Two Week Low4.1100
Shares Short Prior Month824.4k
Average Daily Volume Last 10 Day290.76k
Average Daily Volume In Three Month148.18k
Shares Percent Shares Out2.64%
Gross Margins100.00%
Short Percent Of Float3.75%
Forward Price Earnings-3.10
Float Shares18.28M
Fifty Two Week High10.0000
Enterprise Value To Ebitda-3.47
Fifty Day Average4.8109
Two Hundred Day Average7.0412
Enterprise Value To Revenue31.19
Additionally, see Stocks Correlation. Note that the Logicbio Therapeutics information on this page should be used as a complementary analysis to other Logicbio Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Complementary Tools for Logicbio Therapeutics Stock analysis

When running Logicbio Therapeutics stock analysis, check to measure Logicbio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Logicbio Therapeutics is operating at the current time. Most of Logicbio Therapeutics' stock examination focuses on studying past and present price action to predict the probability of Logicbio Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Logicbio Therapeutics' price. Additionally, you may evaluate how the addition of Logicbio Therapeutics to your portfolios can decrease your overall portfolio volatility.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
The market value of Logicbio Therapeutics is measured differently than its book value, which is the value of Logicbio that is recorded on the company's balance sheet. Investors also form their own opinion of Logicbio Therapeutics stock's value that differs from its market value or its book value, called intrinsic value, which is Logicbio Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Logicbio Therapeutics' market value can be influenced by many factors that don't directly affect Logicbio Therapeutics underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Logicbio Therapeutics' stock value and its price as these two are different measures arrived at by different means. Investors typically determine Logicbio Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Logicbio Therapeutics' stock price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.